- Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1
- First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help…
FDA approves Roche’s Tecentriq plus lurbinectedin as
